Novo Nordisk A/S (NONOF)
USD 69.9
(6.72%)
USD 69.9
(6.72%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 114.62 Billion DKK | 37.66% |
| 2022 | 82.04 Billion DKK | 21.44% |
| 2021 | 65.39 Billion DKK | 12.19% |
| 2020 | 59.27 Billion DKK | 4.19% |
| 2019 | 57.79 Billion DKK | 12.95% |
| 2018 | 51.17 Billion DKK | -1.92% |
| 2017 | 52.14 Billion DKK | 1.06% |
| 2016 | 51.62 Billion DKK | -1.66% |
| 2015 | 49.57 Billion DKK | 37.79% |
| 2014 | 37.92 Billion DKK | 8.65% |
| 2013 | 34.29 Billion DKK | 8.86% |
| 2012 | 32.2 Billion DKK | 43.82% |
| 2011 | 24.93 Billion DKK | 3.01% |
| 2010 | 21.25 Billion DKK | 19.45% |
| 2009 | 17.8 Billion DKK | 25.69% |
| 2008 | 14.86 Billion DKK | 33.44% |
| 2007 | 11.97 Billion DKK | 0.87% |
| 2006 | 11.26 Billion DKK | 15.86% |
| 2005 | 10 Billion DKK | 9.59% |
| 2004 | 8.93 Billion DKK | 41.05% |
| 2003 | 8.02 Billion DKK | -0.73% |
| 2002 | 7.3 Billion DKK | 4.23% |
| 2001 | 6.67 Billion DKK | 18.27% |
| 2000 | 5.27 Billion DKK | 2.15% |
| 1999 | 3.86 Billion DKK | 129.68% |
| 1998 | 2.42 Billion DKK | -9.33% |
| 1997 | 3.47 Billion DKK | 7.15% |
| 1996 | 3.04 Billion DKK | -17.56% |
| 1995 | 3.01 Billion DKK | 7.9% |
| 1994 | 2.89 Billion DKK | 6.92% |
| 1993 | 2.74 Billion DKK | 178.73% |
| 1992 | 1.85 Billion DKK | -47.35% |
| 1991 | 1.99 Billion DKK | 26.89% |
| 1990 | 1.57 Billion DKK | 3.36% |
| 1989 | 1.52 Billion DKK | 20.77% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 35.32 Billion DKK | 23.91% |
| 2024 Q2 | 34.37 Billion DKK | -1.55% |
| 2023 FY | - DKK | 37.66% |
| 2023 Q3 | 32.75 Billion DKK | 22.63% |
| 2023 Q4 | 28.51 Billion DKK | -12.96% |
| 2023 Q1 | 27.57 Billion DKK | 167.38% |
| 2023 Q2 | 26.71 Billion DKK | -3.14% |
| 2022 Q1 | 21 Billion DKK | 52.14% |
| 2022 Q3 | 23.79 Billion DKK | 9.75% |
| 2022 FY | - DKK | 21.44% |
| 2022 Q2 | 21.68 Billion DKK | 3.22% |
| 2022 Q4 | 10.31 Billion DKK | -56.66% |
| 2021 Q3 | 17.38 Billion DKK | 8.7% |
| 2021 Q4 | 13.8 Billion DKK | -20.59% |
| 2021 Q1 | 18.11 Billion DKK | 55.13% |
| 2021 Q2 | 15.99 Billion DKK | -11.68% |
| 2021 FY | - DKK | 12.19% |
| 2020 Q4 | 11.67 Billion DKK | -22.68% |
| 2020 Q2 | 15.09 Billion DKK | -13.28% |
| 2020 Q1 | 17.4 Billion DKK | 82.9% |
| 2020 Q3 | 15.1 Billion DKK | 0.05% |
| 2020 FY | - DKK | 4.19% |
| 2019 Q4 | 9.51 Billion DKK | -36.69% |
| 2019 Q1 | 15.31 Billion DKK | 42.84% |
| 2019 Q2 | 14.57 Billion DKK | -4.79% |
| 2019 Q3 | 15.03 Billion DKK | 3.11% |
| 2019 FY | - DKK | 12.95% |
| 2018 Q2 | 14.01 Billion DKK | -2.55% |
| 2018 Q4 | 10.71 Billion DKK | -14.91% |
| 2018 Q1 | 14.37 Billion DKK | 48.47% |
| 2018 FY | - DKK | -1.92% |
| 2018 Q3 | 12.59 Billion DKK | -10.1% |
| 2017 Q3 | 12.75 Billion DKK | -13.09% |
| 2017 FY | - DKK | 1.06% |
| 2017 Q2 | 14.67 Billion DKK | 1.48% |
| 2017 Q4 | 9.68 Billion DKK | -24.05% |
| 2017 Q1 | 14.45 Billion DKK | 29.0% |
| 2016 Q3 | 13.15 Billion DKK | -0.44% |
| 2016 Q4 | 11.2 Billion DKK | -14.82% |
| 2016 Q1 | 12.95 Billion DKK | 109.68% |
| 2016 Q2 | 13.21 Billion DKK | 1.99% |
| 2016 FY | - DKK | -1.66% |
| 2015 Q4 | 6.17 Billion DKK | -51.05% |
| 2015 Q3 | 12.62 Billion DKK | -3.87% |
| 2015 Q1 | 14.8 Billion DKK | 97.61% |
| 2015 Q2 | 13.13 Billion DKK | -11.31% |
| 2015 FY | - DKK | 37.79% |
| 2014 Q3 | 8.89 Billion DKK | -2.56% |
| 2014 FY | - DKK | 8.65% |
| 2014 Q1 | 8.61 Billion DKK | 17.12% |
| 2014 Q2 | 9.12 Billion DKK | 5.92% |
| 2014 Q4 | 7.49 Billion DKK | -15.77% |
| 2013 Q4 | 7.35 Billion DKK | -12.5% |
| 2013 FY | - DKK | 8.86% |
| 2013 Q1 | 7.87 Billion DKK | -1.72% |
| 2013 Q2 | 8.94 Billion DKK | 13.6% |
| 2013 Q3 | 8.41 Billion DKK | -6.01% |
| 2012 Q1 | 6.26 Billion DKK | 11.96% |
| 2012 Q4 | 8.01 Billion DKK | 4.39% |
| 2012 FY | - DKK | 43.82% |
| 2012 Q3 | 7.67 Billion DKK | -1.55% |
| 2012 Q2 | 7.79 Billion DKK | 24.54% |
| 2011 FY | - DKK | 3.01% |
| 2011 Q2 | 6.36 Billion DKK | 1.68% |
| 2011 Q3 | 6.37 Billion DKK | 0.3% |
| 2011 Q4 | 5.59 Billion DKK | -12.32% |
| 2011 Q1 | 6.25 Billion DKK | 7.38% |
| 2010 Q1 | 5.02 Billion DKK | 53.53% |
| 2010 Q2 | 5.78 Billion DKK | 15.0% |
| 2010 Q3 | 5.76 Billion DKK | -0.35% |
| 2010 Q4 | 5.82 Billion DKK | 1.09% |
| 2010 FY | - DKK | 19.45% |
| 2009 FY | - DKK | 25.69% |
| 2009 Q3 | 3.81 Billion DKK | -10.11% |
| 2009 Q2 | 4.24 Billion DKK | 8.37% |
| 2009 Q1 | 3.91 Billion DKK | 12.95% |
| 2009 Q4 | 3.27 Billion DKK | -14.18% |
| 2008 Q4 | 3.46 Billion DKK | 5.79% |
| 2008 FY | - DKK | 33.44% |
| 2008 Q2 | 2.76 Billion DKK | 1.07% |
| 2008 Q1 | 2.73 Billion DKK | 949.03% |
| 2008 Q3 | 3.27 Billion DKK | 18.43% |
| 2007 Q2 | 2.75 Billion DKK | 26.04% |
| 2007 Q4 | 261.04 Million DKK | -90.14% |
| 2007 FY | - DKK | 0.87% |
| 2007 Q1 | 2.18 Billion DKK | 22.44% |
| 2007 Q3 | 2.64 Billion DKK | -3.72% |
| 2006 Q1 | 2.42 Billion DKK | 29.92% |
| 2006 FY | - DKK | 15.86% |
| 2006 Q4 | 1.78 Billion DKK | -27.34% |
| 2006 Q2 | 2.63 Billion DKK | 8.54% |
| 2006 Q3 | 2.45 Billion DKK | -6.84% |
| 2005 Q4 | 1.86 Billion DKK | -11.22% |
| 2005 FY | - DKK | 9.59% |
| 2005 Q3 | 2.1 Billion DKK | -3.75% |
| 2005 Q2 | 2.18 Billion DKK | 81.02% |
| 2005 Q1 | 1.2 Billion DKK | -26.31% |
| 2004 Q4 | 1.63 Billion DKK | -3.97% |
| 2004 FY | - DKK | 41.05% |
| 2004 Q3 | 1.7 Billion DKK | 12.86% |
| 2004 Q1 | 1.34 Billion DKK | 113.58% |
| 2004 Q2 | 1.51 Billion DKK | 12.16% |
| 2003 Q1 | 5.11 Billion DKK | 140.95% |
| 2003 Q4 | -9.92 Billion DKK | -275.21% |
| 2003 Q3 | 5.66 Billion DKK | 3.29% |
| 2003 FY | - DKK | -0.73% |
| 2003 Q2 | 5.48 Billion DKK | 7.11% |
| 2002 Q1 | 6.02 Billion DKK | 151.82% |
| 2002 Q2 | 5.27 Billion DKK | -12.32% |
| 2002 Q3 | 6.44 Billion DKK | 22.11% |
| 2002 Q4 | -12.49 Billion DKK | -293.91% |
| 2002 FY | - DKK | 4.23% |
| 2001 Q1 | 5.34 Billion DKK | 137.11% |
| 2001 FY | - DKK | 18.27% |
| 2001 Q4 | -11.61 Billion DKK | -274.63% |
| 2001 Q3 | 6.65 Billion DKK | 15.78% |
| 2001 Q2 | 5.74 Billion DKK | 7.47% |
| 2000 Q2 | 6.48 Billion DKK | 16.57% |
| 2000 Q3 | 15.34 Billion DKK | 136.62% |
| 2000 FY | - DKK | 2.15% |
| 2000 Q4 | -14.4 Billion DKK | -193.88% |
| 2000 Q1 | 5.56 Billion DKK | 147.28% |
| 1999 Q2 | 5.02 Billion DKK | 8.45% |
| 1999 Q4 | -11.76 Billion DKK | -302.07% |
| 1999 FY | - DKK | 129.68% |
| 1999 Q1 | 4.63 Billion DKK | 142.23% |
| 1999 Q3 | 5.82 Billion DKK | 15.94% |
| 1998 Q2 | 4.56 Billion DKK | 8.95% |
| 1998 Q1 | 4.19 Billion DKK | 142.09% |
| 1998 Q4 | -10.96 Billion DKK | -317.84% |
| 1998 FY | - DKK | -9.33% |
| 1998 Q3 | 5.03 Billion DKK | 10.22% |
| 1997 Q4 | -9.96 Billion DKK | -330.83% |
| 1997 Q2 | 4.12 Billion DKK | 13.72% |
| 1997 Q1 | 3.62 Billion DKK | 141.58% |
| 1997 FY | - DKK | 7.15% |
| 1997 Q3 | 4.31 Billion DKK | 4.63% |
| 1996 FY | - DKK | -17.56% |
| 1996 Q4 | -8.72 Billion DKK | -337.73% |
| 1996 Q3 | 3.66 Billion DKK | 4.6% |
| 1996 Q2 | 3.5 Billion DKK | 2.12% |
| 1996 Q1 | 3.43 Billion DKK | 140.75% |
| 1995 FY | - DKK | 7.9% |
| 1995 Q4 | -8.42 Billion DKK | -361.95% |
| 1995 Q3 | 3.21 Billion DKK | -9.94% |
| 1995 Q2 | 3.57 Billion DKK | 6.01% |
| 1995 Q1 | 3.37 Billion DKK | 141.51% |
| 1994 Q1 | 3.11 Billion DKK | 144.7% |
| 1994 FY | - DKK | 6.92% |
| 1994 Q4 | -8.12 Billion DKK | -340.61% |
| 1994 Q3 | 3.37 Billion DKK | -1.4% |
| 1994 Q2 | 3.42 Billion DKK | 10.02% |
| 1993 Q4 | -6.96 Billion DKK | -322.29% |
| 1993 Q2 | 3 Billion DKK | 14.37% |
| 1993 Q3 | 3.13 Billion DKK | 4.25% |
| 1993 Q1 | 2.62 Billion DKK | 138.63% |
| 1993 FY | - DKK | 178.73% |
| 1992 Q2 | 2.8 Billion DKK | 5.54% |
| 1992 Q1 | 2.66 Billion DKK | 148.56% |
| 1992 Q4 | -6.79 Billion DKK | -364.96% |
| 1992 FY | - DKK | -47.35% |
| 1992 Q3 | 2.56 Billion DKK | -8.67% |
| 1991 Q4 | -5.48 Billion DKK | -329.06% |
| 1991 Q1 | 2.27 Billion DKK | 145.95% |
| 1991 Q2 | 2.24 Billion DKK | -1.2% |
| 1991 Q3 | 2.39 Billion DKK | 6.4% |
| 1991 FY | - DKK | 30.17% |
| 1990 Q3 | 2.02 Billion DKK | -0.11% |
| 1990 Q4 | -4.95 Billion DKK | -344.08% |
| 1990 Q2 | 2.03 Billion DKK | 4.7% |
| 1990 FY | - DKK | -6.33% |
| 1990 Q1 | 1.94 Billion DKK | 143.86% |
| 1989 Q3 | 1.74 Billion DKK | -0.53% |
| 1989 Q1 | 1.97 Billion DKK | 164.62% |
| 1989 Q2 | 1.75 Billion DKK | -11.07% |
| 1989 Q4 | -4.42 Billion DKK | -353.14% |
| 1989 FY | - DKK | 24.54% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Bioxytran, Inc. | -3.82 Million USD | 3000743.693% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 161467.476% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | 47931941.94% |
| SQZ Biotechnologies Company | -64.14 Million USD | 178814.083% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 4334804.256% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 660025.158% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | -121796.304% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 7462687.457% |
| Marizyme, Inc. | -34.28 Million USD | 334475.967% |
| Genus plc | 73.7 Million USD | -155434.6% |
| Pharming Group N.V. | 9.87 Million USD | -1160464.949% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 7706707.181% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 3231818.766% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 1306860.146% |
| ContraFect Corporation | -64.99 Million USD | 176455.021% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 8177325.412% |
| IMV Inc. | -35.52 Million USD | 322785.937% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 4932883.09% |
| ONE Bio Corp. | 13.61 Million USD | -841952.667% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 237786.358% |
| Mesoblast Limited | -62.38 Million USD | 183830.518% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | 22127285.617% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | -3208998.544% |
| Genscript Biotech Corporation | -248.71 Million USD | 46187.657% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 18125955.858% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 5017808.555% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 1933491.118% |
| Biomind Labs Inc. | -1.03 Million USD | 11080193.838% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 3963311.616% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 1600778.65% |
| Skye Bioscience, Inc. | -13.54 Million USD | 846223.469% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | -1704773844.081% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 1733877.588% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 458516100.0% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 2532668.747% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 2951169.943% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 722411.907% |
| Accustem Sciences Inc. | -3.74 Million USD | 3059795.138% |
| EV Biologics, Inc. | -1.26 Million USD | 9046434.557% |
| Q BioMed Inc. | -617.62 Thousand USD | 18559653.647% |
| GB Sciences, Inc. | -1.41 Million USD | 8073218.598% |
| Alpha Cognition Inc. | -9.7 Million USD | 1181160.297% |
| CSL Limited | 4.78 Billion USD | -2293.589% |
| Agentix Corp. | -1.37 Million USD | 8356469.5% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 289297.998% |
| Enzolytics Inc. | -2.12 Million USD | 5401958.316% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | -11.74 Million USD | 976330.625% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 3742457.206% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 4581664.388% |
| argenx SE | -216.02 Million USD | 53163.319% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 207239.63% |
| HST Global, Inc. | -5303.00 USD | 2161587880.502% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | -9418881.101% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 5572730.044% |
| Halberd Corporation | -74.27 Thousand USD | 154322317.585% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | -1294586.881% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | -30257473.038% |
| Zenith Capital Corp. | -8.6 Million USD | 1332066.07% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 7647610.918% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 4685602.855% |
| AVAX Technologies, Inc. | -6.11 Million USD | 1875377.192% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | 65121200.284% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 5967528.996% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 657993326.566% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | -1.03 Million USD | 11077538.377% |
| Helix BioMedix, Inc. | -1.04 Million USD | 10955627.606% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 6550332.314% |
| Kadimastem Ltd | -2.62 Million USD | 4367949.028% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | -7.55 Million USD | 1517632.264% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | 63300263.456% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| LadRx Corporation | 412.28 Thousand USD | -27803374.798% |
| Cell Source, Inc. | -4.27 Million USD | 2683032.766% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | 31215362.744% |
| Regen BioPharma, Inc. | 1.46 Million USD | -7819302.492% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | 12234383.83% |
| Affymax, Inc. | -14.29 Million USD | 801981.833% |
| Mobile Lads Corp. | -2.24 Million USD | 5114819.661% |
| Itoco Inc. | -1.86 Million USD | 6133289.227% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | 30195822.038% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 10271515.771% |
| International Stem Cell Corporation | 202 Thousand USD | -56746929.703% |
| CytoDyn Inc. | -18.02 Million USD | 635903.428% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | 145046854.989% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | 937353931.057% |
| Qrons Inc. | -40.08 Thousand USD | 285993463.439% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | 23601951.432% |
| SYBLEU INC | -141.57 Thousand USD | 80969366.305% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | -21733276.562% |
| Rebus Holdings, Inc. | -951 Thousand USD | 12053622.608% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 10793689.514% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 217760358.359% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 4656158.738% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 319676.793% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -45 Thousand USD | 254731211.111% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 4186696.056% |
| Neutra Corp. | -181.24 Thousand USD | 63244733.015% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 568724.436% |
| PureTech Health plc | -11.62 Million USD | 985986.299% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 568763.42% |
| IXICO plc | -707 Thousand USD | 16213537.058% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 1491694.014% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 237201.311% |
| CSL Limited | 4.73 Billion USD | -2321.91% |
| Cellectis S.A. | -92.63 Million USD | 123841.31% |